- cafead   May 29, 2018 at 10:42: AM
via Pfizer Inc. (NYSEFE) announced on 5/29/18 that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy.
article source
article source